Base de dados : MEDLINE
Pesquisa : C04.588.274.120 [Categoria DeCS]
Referências encontradas : 2761 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 277 ir para página                         

  1 / 2761 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352306
[Au] Autor:Peraldo-Neia C; Cavalloni G; Fenocchio E; Cagnazzo C; Gammaitoni L; Cereda S; Nasti G; Satolli MA; Aprile G; Reni M; Avallone A; Spadi R; Venesio T; Martin V; Doglioni C; Frattini M; Aglietta M; Leone F
[Ad] Endereço:Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS-Institute of Candiolo, Candiolo, Italy.
[Ti] Título:Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
[So] Source:PLoS One;13(1):e0191593, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved in the resistance to anti-EGFR. Here, we explored the mutation profile of EGFR extracellular domain (ECD), of tyrosine kinase domain (TKD), and its amplification status. EGFR mutational status of exons 12, 18-21 was analyzed in 57 tumors by Sanger sequencing. EGFR amplification was evaluated in 37 tumors by Fluorescent In Situ Hybridization (FISH). Kaplan-Meier curves were calculated using the log-rank test. Six patients had mutations in exon 12 of EGFR ECD and 7 in EGFR TKD. Neither EGFR ECD nor TKD mutations affected progression free survival (PFS) or overall survival (OS) in the entire population. In the panitumumab plus GEMOX (P-GEMOX) arm, ECD mutated patients had a worse OS, while EGFR TKD mutated patients had a trend towards shorter PFS and OS. Overall, the presence of mutations in EGFR or in its transducers did not affect PFS or OS, while the extrahepatic cholangiocarcinoma (ECC) mutated patients had a worse prognosis compared to WT. Nineteen out of 37 tumors were EGFR amplified, but the amplification did not correlate with survival. ECC EGFR amplified patients had improved OS, whereas the amplification significantly correlated with poor PFS (p = 0.03) in gallbladder carcinoma patients. The high molecular heterogeneity is a predominant feature of BTC: the alterations found in this work seem to have a prognostic impact rather than a predictive role towards anti-EGFR therapy.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/tratamento farmacológico
Neoplasias do Sistema Biliar/genética
Genes erbB-1
Mutação
Receptor do Fator de Crescimento Epidérmico/genética
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias dos Ductos Biliares/tratamento farmacológico
Neoplasias dos Ductos Biliares/genética
Neoplasias dos Ductos Biliares/metabolismo
Neoplasias do Sistema Biliar/metabolismo
Colangiocarcinoma/tratamento farmacológico
Colangiocarcinoma/genética
Colangiocarcinoma/metabolismo
Análise Mutacional de DNA
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Neoplasias da Vesícula Biliar/tratamento farmacológico
Neoplasias da Vesícula Biliar/genética
Neoplasias da Vesícula Biliar/metabolismo
Amplificação de Genes
Seres Humanos
Hibridização in Situ Fluorescente
Estimativa de Kaplan-Meier
Compostos Organoplatínicos/administração & dosagem
Compostos Organoplatínicos/uso terapêutico
Prognóstico
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
Receptor do Fator de Crescimento Epidérmico/metabolismo
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Organoplatinum Compounds); 04ZR38536J (oxaliplatin); 0W860991D6 (Deoxycytidine); 6A901E312A (panitumumab); B76N6SBZ8R (gemcitabine); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191593


  2 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277797
[Au] Autor:Falkenstein TA; Götze TO; Ouaissi M; Tempfer CB; Giger-Pabst U; Demtröder C
[Ad] Endereço:Basic Research Laboratories of the Department of Surgery, St. Mary's Hospital, Ruhr University Bochum, Herne, Germany.
[Ti] Título:First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer.
[So] Source:Anticancer Res;38(1):373-378, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients suffering from peritoneal metastasis of biliary tract cancer were treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). PATIENTS AND METHODS: This was a study carried out at a single institution, tertiary referral center certified for therapy of peritoneal disease. Retrospective data analysis was performed of prospective data for PIPAC with intra-peritoneal low-dose doxorubicin (1.5 mg/m ) and cisplatin (7.5 mg/m ) delivered at intervals of 6 weeks. The outcome criteria were microscopic pathological response, survival, and adverse events [Common Terminology Criteria of Adverse Events (v4.0)]. RESULTS: A total of 13 patients (male/female=8/5) with a mean age of 58 (range=37-75) years underwent 17 PIPAC procedures without intraoperative complications. The mean number of PIPAC applications was 1.3 (range=0-3). Due to non-accessibility of the abdominal cavity in two patients (15.4%) and rapid clinical deterioration in six patients (46%), five patients underwent two or more PIPAC applications and were, therefore, eligible for histological analysis to assess carcinoma regression. Overall tumor regression of any degree was determined in 4/5 patients. An overall median survival of 85 days (95% confidence interval(CI)=59.2-110.4 days) after the first PIPAC application was observed. No complications greater than Common Terminology Criteria of Adverse Events (v4.0) level 2 occurred. CONCLUSION: PIPAC can induce objective regression of systemic chemotherapy-resistant peritoneal metastasis of biliary tract cancer. However, due to a rapid clinical deterioration of the patients, almost two-thirds of the patients cannot undergo repetitive PIPAC courses.
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/uso terapêutico
Neoplasias do Sistema Biliar/patologia
Infusões Parenterais/métodos
Neoplasias Peritoneais/tratamento farmacológico
Neoplasias Peritoneais/secundário
Terapia de Salvação/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias do Sistema Biliar/tratamento farmacológico
Cisplatino/uso terapêutico
Doxorrubicina/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias Peritoneais/mortalidade
Peritônio/patologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 80168379AG (Doxorubicin); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  3 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28921531
[Au] Autor:Jiang W; Shen Y; Ding Y; Ye C; Zheng Y; Zhao P; Liu L; Tong Z; Zhou L; Sun S; Zhang X; Teng L; Timko MP; Fan L; Fang W
[Ad] Endereço:Cancer Biotherapy Center, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
[Ti] Título:A naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system.
[So] Source:Int J Cancer;142(2):357-368, 2018 Jan 15.
[Is] ISSN:1097-0215
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Synchronous multifocal tumors are common in the hepatobiliary and pancreatic system but because of similarities in their histological features, oncologists have difficulty in identifying their precise tissue clonal origin through routine histopathological methods. To address this problem and assist in more precise diagnosis, we developed a computational approach for tissue origin diagnosis based on naive Bayes algorithm (TOD-Bayes) using ubiquitous RNA-Seq data. Massive tissue-specific RNA-Seq data sets were first obtained from The Cancer Genome Atlas (TCGA) and ∼1,000 feature genes were used to train and validate the TOD-Bayes algorithm. The accuracy of the model was >95% based on tenfold cross validation by the data from TCGA. A total of 18 clinical cancer samples (including six negative controls) with definitive tissue origin were subsequently used for external validation and 17 of the 18 samples were classified correctly in our study (94.4%). Furthermore, we included as cases studies seven tumor samples, taken from two individuals who suffered from synchronous multifocal tumors across tissues, where the efforts to make a definitive primary cancer diagnosis by traditional diagnostic methods had failed. Using our TOD-Bayes analysis, the two clinical test cases were successfully diagnosed as pancreatic cancer (PC) and cholangiocarcinoma (CC), respectively, in agreement with their clinical outcomes. Based on our findings, we believe that the TOD-Bayes algorithm is a powerful novel methodology to accurately identify the tissue origin of synchronous multifocal tumors of unknown primary cancers using RNA-Seq data and an important step toward more precision-based medicine in cancer diagnosis and treatment.
[Mh] Termos MeSH primário: Algoritmos
Teorema de Bayes
Neoplasias do Sistema Biliar/diagnóstico
Biomarcadores Tumorais/genética
Linhagem da Célula/genética
Neoplasias Hepáticas/diagnóstico
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Pancreáticas/diagnóstico
[Mh] Termos MeSH secundário: Neoplasias do Sistema Biliar/genética
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Neoplasias Hepáticas/genética
Neoplasias Primárias Múltiplas/genética
Neoplasias Pancreáticas/genética
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170919
[St] Status:MEDLINE
[do] DOI:10.1002/ijc.31054


  4 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982868
[Au] Autor:Ikemoto T; Shimada M; Ishikawa D; Kawashita Y; Teraoku H; Yoshikawa M; Yamada S; Saito YU; Morine Y; Imura S
[Ad] Endereço:Department of Digestive and Transplant Surgery, Institute of Health Bioscience, Graduate School of Medicine, University of Tokushima, Tokushima, Japan ikemoto.tetsuya@tokushima-u.ac.jp.
[Ti] Título:Peripheral Tr1 and Foxp3 Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers.
[So] Source:Anticancer Res;37(10):5541-5552, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Recently CD4 CD49b LAG3 regulatory T (Tr1) cells are reported to be IL-10 driven, have strong regulatory activities. Thus, this study aimed to investigate whether Treg and Tr1 cells participate in immunological status against cancer. PATIENTS AND METHODS: Peripheral blood was withdrawn from patients (n=78), and healthy volunteers as controls (n=23). The peripheral blood mononuclear cells were subjected to FACScan analysis after labeling with anti-CD4, -CD25, - Foxp3, -CD49b and -LAG3 antibodies. Resected specimens were stained for IL-10. Patients' clinical course and clinicopathological factors were compared. RESULTS: Tr1 was significantly higher in patients with cancer (p=0.02). Among patients who underwent R0 resection, those with early recurrence had a significantly higher pre-/post-operative Tr1 ratio (p<0.05). Median pre-/post-operative ratios of Foxp3Tregs and Tr1s predicted early recurrence with 85.6% sensitivity and 93.3% specificity. Disease-free survival was significantly lower in patients with high IL-10 expression in resected specimens. CONCLUSION: Peripheral Tregs and Tr1 indicate immunological state against cancer.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/imunologia
Fatores de Transcrição Forkhead/imunologia
Neoplasias Hepáticas/imunologia
Recidiva Local de Neoplasia
Neoplasias Pancreáticas/imunologia
Linfócitos T Reguladores/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias do Sistema Biliar/sangue
Neoplasias do Sistema Biliar/patologia
Neoplasias do Sistema Biliar/cirurgia
Estudos de Casos e Controles
Intervalo Livre de Doença
Feminino
Citometria de Fluxo
Fatores de Transcrição Forkhead/sangue
Seres Humanos
Imunofenotipagem/métodos
Interleucina-10/imunologia
Estimativa de Kaplan-Meier
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/cirurgia
Contagem de Linfócitos
Masculino
Meia-Idade
Neoplasias Pancreáticas/sangue
Neoplasias Pancreáticas/patologia
Neoplasias Pancreáticas/cirurgia
Fenótipo
Valor Preditivo dos Testes
Fatores de Risco
Fatores de Tempo
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Evasão Tumoral
Microambiente Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (FOXP3 protein, human); 0 (Forkhead Transcription Factors); 0 (IL10 protein, human); 130068-27-8 (Interleukin-10)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  5 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28870921
[Au] Autor:Shimura T; Shibata M; Gonda K; Kofunato Y; Okada R; Ishigame T; Kimura T; Kenjo A; Kono K; Marubashi S
[Ad] Endereço:Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, Fukushima, Japan tshimura@fmu.ac.jp.
[Ti] Título:Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer.
[So] Source:Anticancer Res;37(9):4979-4986, 2017 09.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Pancreatobiliary cancer is a disease associated with a dismal prognosis and limited treatment options. The aim of the present study was to clarify the usefulness of circulating galectin-3 in pancreatobiliary cancer. PATIENTS AND METHODS: We examined serum galectin-3 concentrations in 45 patients with pancreatobiliary cancer. Receiver operating characteristic curves were utilized to evaluate the accuracy of circulating galectin-3 to discriminate pancreatobiliary cancer patients from controls and predict the prognostic outcomes. RESULTS: Circulating galectin-3 had diagnostic value at the cut-off level of 6.2 ng/ml, and the patients' overall survival was predictable at the cut-off level of 10.3 ng/ml. Furthermore, circulating galectin-3 ≥10.3 ng/ml was an independent prognostic marker in pancreatobiliary cancer. Regarding biliary cancer, higher galectin-3 was associated with malnutrition. On the other hand, regarding pancreatic cancer, higher galectin-3 levels were associated with higher inflammatory parameters. CONCLUSION: Galectin-3 can be a useful biomarker in patients with pancreatobiliary cancer.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/mortalidade
Biomarcadores Tumorais/sangue
Galectina 3/sangue
Neoplasias Pancreáticas/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias do Sistema Biliar/sangue
Neoplasias do Sistema Biliar/patologia
Estudos de Casos e Controles
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Estadiamento de Neoplasias
Neoplasias Pancreáticas/sangue
Neoplasias Pancreáticas/patologia
Prognóstico
Curva ROC
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Galectin 3)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE


  6 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28854347
[Au] Autor:Wang HL; Kim CJ; Koo J; Zhou W; Choi EK; Arcega R; Chen ZE; Wang H; Zhang L; Lin F
[Ti] Título:Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas.
[So] Source:Arch Pathol Lab Med;141(9):1155-1180, 2017 Sep.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONTEXT: - Immunomarkers with diagnostic, therapeutic, or prognostic values have been increasingly used to maximize the benefits of clinical management of patients with neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. OBJECTIVES: - To review the characteristics of immunomarkers that are commonly used in surgical pathology practice for neoplasms of the gastrointestinal tract, liver, biliary tract, and pancreas, and to summarize the clinical usefulness of immunomarkers that have been discovered in recent years in these fields. DATA SOURCES: - Data sources include literature review, authors' research data, and personal practice experience. CONCLUSIONS: - Immunohistochemistry is an indispensable tool for the accurate diagnosis of neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Useful immunomarkers are available to help distinguish malignant neoplasms from benign conditions, determine organ origins, and subclassify neoplasms that are morphologically and biologically heterogeneous. Specific immunomarkers are also available to help guide patient treatment and assess disease aggressiveness, which are keys to the success of personalized medicine. Pathologists will continue to play a critical role in the discovery, validation, and application of new biomarkers, which will ultimately improve patient care.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/análise
Neoplasias do Sistema Digestório/diagnóstico
Imuno-Histoquímica/métodos
Patologia Cirúrgica/métodos
Oncologia Cirúrgica/métodos
[Mh] Termos MeSH secundário: Neoplasias do Sistema Biliar/diagnóstico
Neoplasias Gastrointestinais/diagnóstico
Seres Humanos
Neoplasias Hepáticas/diagnóstico
Neoplasias Pancreáticas/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0489-RA


  7 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28731820
[Au] Autor:Granata V; Fusco R; Catalano O; Filice S; Avallone A; Piccirillo M; Leongito M; Palaia R; Grassi R; Izzo F; Petrillo A
[Ad] Endereço:1 Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, IRCCS di Napol, Naples, Italy.
[Ti] Título:Uncommon neoplasms of the biliary tract: radiological findings.
[So] Source:Br J Radiol;90(1078):20160561, 2017 Oct.
[Is] ISSN:1748-880X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To report our cancer centre experience in the biliary tumours incidence other than cholangiocellular-carcinoma, emphasizing the radiological features. METHODS: 197 patients with biliary disease undergoing Gd-EOB-DTPA-enhanced MRI were reviewed. Four radiologists evaluated retrospectively size, structure, anatomical site and signal intensity of lesions on MRI. Enhancement-pattern during the arterial-, portal- and late-phase on ultrasound, CT and MR study was assessed as well as the enhancement pattern during the hepatobiliary-phase on MRI. RESULTS: 23 patients were selected. The lesion was intraductal in 5 cases, periductal in 14 and intrahepatic in 4. 16 lesions were solid, 5 uniloculated cystic and 2 complex cystic. In five patients the lesion was simple cyst, with a signal intensity in T weighted (T1W) and T weighted (T2W) similar to the gallbladder. In two patients with complex cystic lesion, the solid component was heterogeneously hypointense in T W, hyperintense in T W with a restricted diffusion. The solid component showed heterogeneous contrast-enhancement on CT, MR and ultrasound. The tumour was intrahepatic in two patients, with signal hypointense in T W and hyperintense in T W. Diffusion was restricted. The lesions showed heterogeneous contrast-enhancement. The periductal lesions were hypointense in T W, hyperintense in T W with restricted diffusion. The lesion showed progressive contrast-enhancement. Peribiliary melanoma was hyperintense in T W, hyperintense in T W with restricted diffusion and progressively contrast-enhanced. CONCLUSION: Biliary tumours can have a wide spectrum of radiologic appearances and consequently represent a diagnostic challenge for the radiologist. Advances in knowledge: MRI is the technique of choice in diagnosing biliary tumours, including rare (non-CCC) tumours.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias do Sistema Biliar/epidemiologia
Feminino
Seres Humanos
Incidência
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Estudos Retrospectivos
Tomografia Computadorizada por Raios X
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1259/bjr.20160561


  8 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28708225
[Au] Autor:Il Yu J; Chul Park H; Hoon Lim D; Oh Park J; Suk Park Y; Tae Kim S; Ho Choi S; Wook Choi D; Woong Han I; Seok Heo J
[Ad] Endereço:Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul - Korea.
[Ti] Título:Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer.
[So] Source:Tumori;103(4):345-352, 2017 Jul 31.
[Is] ISSN:2038-2529
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of this study was to investigate the clinical outcomes and prognostic factors of concurrent chemoradiotherapy (CCRT) for locally recurrent biliary tract cancer (BTC) after curative surgical resection. METHODS: We performed a retrospective cohort study of patients with locally recurrent BTC treated with CCRT between October 2004 and December 2013. The study included and analyzed 42 patients with a history of curative-intent surgical resection of confirmed adenocarcinoma originating from the biliary tract. RESULTS: The median time to recurrence after surgery was 16.1 months (range, 4.5-77.8 months). Median follow-up after CCRT was 26.9 months (range, 5.2-81.9) with no grade 3 or higher gastrointestinal toxicities. Analysis of the first site of failure showed local progression (LP) developed in 20 patients (47.6%); among these, 16 (38.1%) had isolated LP. The median values were 15.8 months (range, 1.7-81.7) for LP-free survival (LPFS), 10.6 months (range, 1.7 - 81.7) for progression-free survival (PFS) and 41.2 months (range, 5.2-81.9) for overall survival (OS). Multivariate analysis showed that the level of pre-CCRT carbohydrate antigen (CA) 19-9 and the chemotherapy regimen were significant prognostic factors for LPFS and PFS; pT stage was the only significant prognostic factor for OS. CONCLUSIONS: CCRT for locally recurrent BTC showed promising outcomes as a salvage modality, but LP was still frequent. The pre-CCRT CA 19-9 level and the chemotherapy regimen were prognostic factors for LPFS and PFS.
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar/tratamento farmacológico
Neoplasias do Sistema Biliar/radioterapia
Recidiva Local de Neoplasia/tratamento farmacológico
Recidiva Local de Neoplasia/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Neoplasias do Sistema Biliar/patologia
Quimiorradioterapia/métodos
Estudos de Coortes
Intervalo Livre de Doença
Feminino
Fluoruracila/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia/patologia
Estudos Retrospectivos
Terapia de Salvação/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.5301/tj.5000666


  9 / 2761 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28668864
[Au] Autor:Okano N; Kasuga A; Kawai K; Kobayashi T; Naruge D; Nagashima F; Furuse J
[Ad] Endereço:Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan naohiro-okano@ks.kyorin-u.ac.jp.
[Ti] Título:Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
[So] Source:Anticancer Res;37(7):3711-3715, 2017 07.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Vascular endothelial growth factor receptor (VEGFR) has been identified as a treatment target for biliary tract cancer (BTC) and axitinib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-1/2/3. This study was conducted as a preliminary evaluation of the safety and efficacy of axitinib for patients with advanced BTC. PATIENTS AND METHODS: Patients refractory to gemcitabine-based regimens were administered axitinib at the dose of 5 mg twice daily. RESULTS: Five patients (3 male and 2 female) with a median age of 68 years were enrolled. Although 3 patients developed treatment-related grade 3/4 adverse events (AEs), none of these patients required discontinuation of the protocol treatment due to the AEs. Partial response (PR) was achieved in 1 patient, with a 67% reduction. The response was classified as stable disease (SD) in 3 patients and as progressive disease (PD) in 1 patient. Overall survival (OS) and progression-free survival (PFS) ranged from 2.0 to 19.9 months and 1.5 to 7.4 months, respectively. CONCLUSION: This preliminary study suggested that axitinib is well-tolerated and might exert promising activity in patients with BTC.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Neoplasias do Sistema Biliar/tratamento farmacológico
Imidazóis/uso terapêutico
Indazóis/uso terapêutico
Inibidores de Proteínas Quinases/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/efeitos adversos
Neoplasias do Sistema Biliar/diagnóstico por imagem
Neoplasias do Sistema Biliar/patologia
Desoxicitidina/efeitos adversos
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Resistência a Medicamentos Antineoplásicos
Feminino
Seres Humanos
Imidazóis/efeitos adversos
Indazóis/efeitos adversos
Linfonodos/diagnóstico por imagem
Linfonodos/patologia
Metástase Linfática/diagnóstico por imagem
Metástase Linfática/patologia
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Inibidores de Proteínas Quinases/efeitos adversos
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Carga Tumoral/efeitos dos fármacos
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Imidazoles); 0 (Indazoles); 0 (Protein Kinase Inhibitors); 0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine); C9LVQ0YUXG (axitinib)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170703
[St] Status:MEDLINE


  10 / 2761 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647955
[Au] Autor:Isayama H; Nakai Y; Fujisawa T
[Ad] Endereço:Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
[Ti] Título:Which Is Crucial, Strengthen the Foundation or Building the Dream House?
[So] Source:Gut Liver;11(4):453-454, 2017 07 15.
[Is] ISSN:2005-1212
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias do Sistema Biliar
Sonhos
Neoplasias Pancreáticas
[Mh] Termos MeSH secundário: Stents Farmacológicos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170626
[St] Status:MEDLINE
[do] DOI:10.5009/gnl17226



página 1 de 277 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde